Jeffrey S. Friedman

Celsense, Inc. is a Pittsburgh-based medical technology company that has developed a magnetic resonance imaging (MRI) contrast agent technology platform to enable the non-invasive visualization of cells in living subjects. The Company's products are based on proprietary chemistry that allows for the targeting and labeling of cells with magnetic nanoparticles. This enables the visualization of cells in vivo using standard MRI scanners. The Company's products are being developed for use in a variety of applications, including cancer diagnostics, immunology and cell therapy.

Jeffrey S. Friedman is a Board Member at PetDx. Jeffrey was previously with DTxPharma and MatriSys Bioscience, Inc. Jeffrey has also been a Member of the Board of Directors at Celsense, Inc.

Jeffrey S. Friedman started their educational career by getting a Bachelor of Science in Biology/Biological Sciences, General from the Massachusetts Institute of Technology. Jeffrey then went on to get their Doctor of Medicine (MD) from Stanford University School of Medicine in the field of medicine. After that, they completed their internship/residency in the Pediatrics Residency Program at Boston Children's Hospital. Jeffrey then went on to get their Doctor of Philosophy (Ph.D.) in Cancer Biology from Stanford University. Lastly, they completed a Fellowship in Pediatric Hematology-Oncology Research at the Dana Farber Cancer Institute. Jeffrey S. Friedman is certified by The Medical Board of California in California Medical License.